Jasper Therapeutics posts Q2 2025 results update

Jasper Therapeutics, Inc. furnished an 8-K to share that it issued a press release on August 13, 2025 reporting its financial results for the quarter ended June 30, 2025 and providing a corporate update.

Rhea-AI Filing Summary

Jasper Therapeutics, Inc. furnished an 8-K to share that it issued a press release on August 13, 2025 reporting its financial results for the quarter ended June 30, 2025 and providing a corporate update. The press release is attached as Exhibit 99.1, and the company notes that this information is furnished, not filed, so it is not subject to certain Exchange Act liabilities and is not automatically incorporated into other securities filings unless specifically referenced.

Insights

Equity research analyst

Routine 8-K furnishing Q2 2025 results via press release.

Jasper Therapeutics, Inc. reports its quarter ended June 30, 2025 results and a corporate update through a press release furnished on an 8-K. This is the standard mechanism many companies use to make quarterly information broadly available to the market.

The company explicitly states that the press release and related information are being furnished rather than filed under the Exchange Act. That distinction limits how this disclosure is incorporated into other securities documents and how certain liability provisions apply, which is common for earnings releases.

Because the excerpt does not include the underlying financial figures or qualitative details, the business impact of the quarter’s performance cannot be evaluated here. Investors would look to the attached Exhibit 99.1 for revenue, expenses, cash position, and any strategic commentary that might influence their view.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Jasper Therapeutics (JSPR) disclose in this 8-K?

Jasper Therapeutics, Inc. disclosed that it issued a press release on August 13, 2025 reporting its financial results for the quarter ended June 30, 2025 and providing a corporate update.

Which period’s results does Jasper Therapeutics (JSPR) discuss?

The company’s press release reports its financial results for the quarter ended June 30, 2025 and includes a corporate update.

How were Jasper Therapeutics’ Q2 2025 results released to investors?

The results and corporate update were released in a press release dated August 13, 2025, which is furnished as Exhibit 99.1 to the 8-K.

Is Jasper Therapeutics’ Q2 2025 press release considered filed with the SEC?

No. The company states the information in Item 2.02, including Exhibit 99.1, is being furnished, not filed, so it is not subject to Section 18 liability and is not incorporated into other filings unless specifically referenced.

What exhibits are attached to this Jasper Therapeutics (JSPR) 8-K?

The 8-K includes Exhibit 99.1, the press release dated August 13, 2025, and Exhibit 104, the cover page interactive data file in iXBRL format.

Who signed the Jasper Therapeutics 8-K reporting Q2 2025 results?

The report was signed on behalf of Jasper Therapeutics, Inc. by Herb Cross, the company’s Chief Financial Officer, dated August 13, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/13/2025 - 04:10 PM Learn about SEC filing dates

false 0001788028 0001788028 2025-08-13 2025-08-13 0001788028 JSPR:VotingCommonStockParValue0.0001PerShareMember 2025-08-13 2025-08-13 0001788028 JSPR:RedeemableWarrantsEachTenWarrantsExercisableForOneShareOfVotingCommonStockAtExercisePriceOf115.00Member 2025-08-13 2025-08-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 13, 2025

JASPER THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware		001-39138		84-2984849
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

2200 Bridge Pkwy Suite #102
Redwood City, California 94065

(Address of Principal Executive Offices) (Zip Code)

(650) 549-1400

Registrant’s telephone number, including area code

N/A

(Former Name, or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

(Title of each class)		(Trading Symbol)		(Name of exchange on which registered)
Voting Common Stock, par value $0.0001 per share		JSPR		The Nasdaq Stock Market LLC
Redeemable Warrants, each ten warrants exercisable for one share of Voting Common Stock at an exercise price of $115.00		JSPRW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 13, 2025, Jasper Therapeutics, Inc. issued a press release reporting its financial results for the quarter ended June 30, 2025 and providing a corporate update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

In accordance with General Instructions B.2 of Form 8-K, the information in this Item 2.02, including the press release attached hereto as Exhibit 99.1, is being furnished under Item 2.02 and Item 9.01 of Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release, dated August 13, 2025.
104		Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	JASPER THERAPEUTICS, INC.
Date: August 13, 2025	By:	/s/ Herb Cross
		Name:	Herb Cross
		Title:	Chief Financial Officer

2